US Capitol Capsule: White House warns FDA budget cuts would severely limit agency
This article was originally published in Scrip
If the Senate adopts legislation passed by the House on 16 June that seeks to cut the US FDA's discretionary funding for fiscal year 2012 by $285 million, or 11.5% below FY 2011's level, the agency's ability to protect the public health, ensure food and medical products are safe and improve Americans' access to generics and biosimilars would be severely limited, the White House Office of Management and Budget asserted last week.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.